CD274 and neoplasm: Clinically, high proportions of HLA‐DR+ tumor cells are linked to poor survival outcomes, especially when accompanied by elevated PD‐L1 expression, suggesting that HLA‐DR+ tumor cells may serve as a potential predictive biomarker for immunotherapy efficacy in HCC.